20.92 USD
+0.21 (+1.01%)
21.31 USD
+0.39 (+1.86%)
We assign a fundamental rating of 2 out of 10 to TNDM. TNDM was compared to 187 industry peers in the Health Care Equipment & Supplies industry. TNDM has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, TNDM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
TNDM had negative earnings in the past year.
In the past year TNDM has reported a negative cash flow from operations.
In the past 5 years TNDM reported 4 times negative net income.
TNDM had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
TNDM has a Return On Assets (-23.25%) which is in line with its industry peers.
TNDM's Return On Equity of -152.95% is on the low side compared to the rest of the industry. TNDM is outperformed by 68.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.25% | ||
| ROE | -152.95% | ||
| ROIC | N/A |
ROA(3y)-14.09%
ROA(5y)-9.07%
ROE(3y)-42.99%
ROE(5y)-26.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 53.23%, TNDM is in line with its industry, outperforming 48.13% of the companies in the same industry.
In the last couple of years the Gross Margin of TNDM has remained more or less at the same level.
TNDM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.23% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
TNDM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TNDM has more shares outstanding
TNDM has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TNDM is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.47, we must say that TNDM is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TNDM (0.47) is comparable to the rest of the industry.
A Debt/Equity ratio of 2.37 is on the high side and indicates that TNDM has dependencies on debt financing.
The Debt to Equity ratio of TNDM (2.37) is worse than 82.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.37 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.47 |
ROIC/WACCN/A
WACC7.3%
2.3 Liquidity
A Current Ratio of 2.44 indicates that TNDM has no problem at all paying its short term obligations.
With a Current ratio value of 2.44, TNDM perfoms like the industry average, outperforming 48.66% of the companies in the same industry.
TNDM has a Quick Ratio of 1.90. This is a normal value and indicates that TNDM is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.90, TNDM is in line with its industry, outperforming 49.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.44 | ||
| Quick Ratio | 1.9 |
3. Growth
3.1 Past
TNDM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.53%, which is quite good.
TNDM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.87%.
Measured over the past years, TNDM shows a very strong growth in Revenue. The Revenue has been growing by 21.01% on average per year.
EPS 1Y (TTM)16.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.43%
Revenue 1Y (TTM)17.87%
Revenue growth 3Y10.19%
Revenue growth 5Y21.01%
Sales Q2Q%2.17%
3.2 Future
TNDM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.44% yearly.
TNDM is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.13% yearly.
EPS Next Y-29.58%
EPS Next 2Y15.78%
EPS Next 3Y22.24%
EPS Next 5Y20.44%
Revenue Next Year10.11%
Revenue Next 2Y10.15%
Revenue Next 3Y9.87%
Revenue Next 5Y9.13%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TNDM. In the last year negative earnings were reported.
Also next year TNDM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TNDM's earnings are expected to grow with 22.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.78%
EPS Next 3Y22.24%
5. Dividend
5.1 Amount
TNDM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
20.92
+0.21 (+1.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners115.56%
Inst Owner Change-5.38%
Ins Owners0.72%
Ins Owner Change9.36%
Market Cap1.42B
Revenue(TTM)1.01B
Net Income(TTM)-203.37M
Analysts71.33
Price Target22.39 (7.03%)
Short Float %13.1%
Short Ratio4.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.74%
Min EPS beat(2)-18.66%
Max EPS beat(2)3.18%
EPS beat(4)2
Avg EPS beat(4)20.77%
Min EPS beat(4)-18.66%
Max EPS beat(4)104.27%
EPS beat(8)5
Avg EPS beat(8)15.83%
EPS beat(12)5
Avg EPS beat(12)-40.04%
EPS beat(16)5
Avg EPS beat(16)-129.71%
Revenue beat(2)1
Avg Revenue beat(2)1.01%
Min Revenue beat(2)-1.1%
Max Revenue beat(2)3.12%
Revenue beat(4)3
Avg Revenue beat(4)4.09%
Min Revenue beat(4)-1.1%
Max Revenue beat(4)9.97%
Revenue beat(8)6
Avg Revenue beat(8)4.19%
Revenue beat(12)6
Avg Revenue beat(12)1.79%
Revenue beat(16)8
Avg Revenue beat(16)1.24%
PT rev (1m)7.57%
PT rev (3m)-1.7%
EPS NQ rev (1m)5.55%
EPS NQ rev (3m)11.66%
EPS NY rev (1m)11.14%
EPS NY rev (3m)11.92%
Revenue NQ rev (1m)-2.34%
Revenue NQ rev (3m)-3.06%
Revenue NY rev (1m)0.29%
Revenue NY rev (3m)0.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.41 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 10.67 | ||
| P/tB | 10.67 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.44
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-1.05
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS14.85
BVpS1.96
TBVpS1.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.25% | ||
| ROE | -152.95% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.23% | ||
| FCFM | N/A |
ROA(3y)-14.09%
ROA(5y)-9.07%
ROE(3y)-42.99%
ROE(5y)-26.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-0.58%
F-Score4
Asset Turnover1.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.37 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 360.22% | ||
| Cap/Sales | 6.23% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.44 | ||
| Quick Ratio | 1.9 | ||
| Altman-Z | 0.47 |
F-Score4
WACC7.3%
ROIC/WACCN/A
Cap/Depr(3y)341.43%
Cap/Depr(5y)300.44%
Cap/Sales(3y)6.42%
Cap/Sales(5y)5.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.43%
EPS Next Y-29.58%
EPS Next 2Y15.78%
EPS Next 3Y22.24%
EPS Next 5Y20.44%
Revenue 1Y (TTM)17.87%
Revenue growth 3Y10.19%
Revenue growth 5Y21.01%
Sales Q2Q%2.17%
Revenue Next Year10.11%
Revenue Next 2Y10.15%
Revenue Next 3Y9.87%
Revenue Next 5Y9.13%
EBIT growth 1Y34.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.89%
EBIT Next 3Y43.14%
EBIT Next 5Y30.43%
FCF growth 1Y-47.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.98%
OCF growth 3Y-39.87%
OCF growth 5Y-10.38%
TANDEM DIABETES CARE INC / TNDM FAQ
What is the ChartMill fundamental rating of TANDEM DIABETES CARE INC (TNDM) stock?
ChartMill assigns a fundamental rating of 2 / 10 to TNDM.
What is the valuation status for TNDM stock?
ChartMill assigns a valuation rating of 1 / 10 to TANDEM DIABETES CARE INC (TNDM). This can be considered as Overvalued.
Can you provide the profitability details for TANDEM DIABETES CARE INC?
TANDEM DIABETES CARE INC (TNDM) has a profitability rating of 1 / 10.
How financially healthy is TANDEM DIABETES CARE INC?
The financial health rating of TANDEM DIABETES CARE INC (TNDM) is 2 / 10.